{"id":15386,"date":"2023-08-04T09:28:00","date_gmt":"2023-08-04T01:28:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15386"},"modified":"2024-11-28T09:33:13","modified_gmt":"2024-11-28T01:33:13","slug":"huidagene-strikes-licensing-deal-with-kactus-biosystems-for-gene-editing-enzyme-hfcas12max","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15386","title":{"rendered":"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max"},"content":{"rendered":"\n

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce and sell hfCas12Max for grade proteins in Greater China, along with a general license for the production and sales of GMP grade products. HuidaGene is set to receive the corresponding commercial share of hfCas12Max.<\/p>\n\n\n\n

Advantages of hfCas12Max Over Traditional CRISPR Systems<\/strong>
HfCas12Max has been developed using HuidaGene\u2019s HGPRECISE (HuidaGene\u2013Platform for Rational Engineering of CRISPR-Cas Identification by Synergic Expertise) platform. This cutting-edge enzyme boasts higher target editing activity and significantly lower off-target editing activity compared to the widely used CRISPR-Cas9 and Cas12a, Cas12b, and Cas12e systems. This advancement positions hfCas12Max as a potentially more precise and safer tool in the field of gene editing.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[111,2091,2429],"class_list":["post-15386","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-crispr","tag-huidagene-biotechnology","tag-kactus-biosystems"],"yoast_head":"\nHuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce and sell hfCas12Max for grade proteins in Greater China, along with a general license for the production and sales of GMP grade products. HuidaGene is set to receive the corresponding commercial share of hfCas12Max.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15386\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-04T01:28:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-28T01:33:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15386#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15386\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max\",\"datePublished\":\"2023-08-04T01:28:00+00:00\",\"dateModified\":\"2024-11-28T01:33:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15386\"},\"wordCount\":181,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRISPR\",\"HuidaGene Biotechnology\",\"Kactus Biosystems\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15386#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15386\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15386\",\"name\":\"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-04T01:28:00+00:00\",\"dateModified\":\"2024-11-28T01:33:13+00:00\",\"description\":\"China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce and sell hfCas12Max for grade proteins in Greater China, along with a general license for the production and sales of GMP grade products. HuidaGene is set to receive the corresponding commercial share of hfCas12Max.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15386\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max - Insight, China's Pharmaceutical Industry","description":"China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce and sell hfCas12Max for grade proteins in Greater China, along with a general license for the production and sales of GMP grade products. HuidaGene is set to receive the corresponding commercial share of hfCas12Max.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15386","og_locale":"en_US","og_type":"article","og_title":"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15386","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-04T01:28:00+00:00","article_modified_time":"2024-11-28T01:33:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15386#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15386"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max","datePublished":"2023-08-04T01:28:00+00:00","dateModified":"2024-11-28T01:33:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15386"},"wordCount":181,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRISPR","HuidaGene Biotechnology","Kactus Biosystems"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15386#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15386","url":"https:\/\/flcube.com\/?p=15386","name":"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-04T01:28:00+00:00","dateModified":"2024-11-28T01:33:13+00:00","description":"China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced a licensing agreement with fellow Shanghai-based firm Kactus Biosystems, a company specializing in target protein and raw enzyme production. The agreement pertains to the new gene editing tool enzyme, hfCas12Max. According to the terms, Kactus will secure an exclusive license to produce and sell hfCas12Max for grade proteins in Greater China, along with a general license for the production and sales of GMP grade products. HuidaGene is set to receive the corresponding commercial share of hfCas12Max.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15386"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HuidaGene Strikes Licensing Deal with Kactus Biosystems for Gene Editing Enzyme hfCas12Max"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15386"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15386\/revisions"}],"predecessor-version":[{"id":15388,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15386\/revisions\/15388"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}